Clifford Reed, MD
Neurology · West Reading, PANPI 1649281833
Payments from drug & device makers
Across 867 payments — averaging $1015.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$542K
- EMD Serono, Inc.$133K
- Biogen$69K
- Sanofi$52K
- Genentech USA, Inc.$46K
- Bristol Myers Squibb$22K
- plus $17K from 30 others
Across 3 payments — averaging $1142.58 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- F. Hoffmann-la Roche AG$3K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 89 | $541,666 |
| EMD Serono, Inc. | 248 | $133,324 |
| Biogen | 135 | $69,170 |
| Sanofi | 96 | $51,894 |
| Genentech USA, Inc. | 71 | $45,918 |
| Bristol Myers Squibb | 68 | $21,777 |
| E.r. Squibb & Sons, L.L.C. | 15 | $11,526 |
| Genentech, Inc. | 15 | $1,221 |
| Amgen(2 entities) | 26 | $1,175 |
| TG Therapeutics, Inc. | 9 | $683 |
| Teva Pharmaceuticals USA, Inc. | 9 | $498 |
| Supernus Pharmaceuticals, Inc. | 47 | $472 |
| AbbVie(2 entities) | 6 | $298 |
| Sanofi-aventis U.S. LLC | 3 | $214 |
| Axsome Therapeutics, Inc. | 2 | $131 |
| Impel Pharmaceuticals Inc. | 1 | $115 |
| SK Life Science, Inc. | 1 | $67 |
| Acorda Therapeutics, Inc | 2 | $66 |
| Greenwich Biosciences, Inc. | 2 | $46 |
| Pfizer | 2 | $34 |
| Assertio Therapeutics, Inc. | 2 | $32 |
| Adamas Pharmaceuticals, Inc. | 2 | $30 |
| Arbor Pharmaceuticals, Inc. | 2 | $30 |
| Amneal Pharmaceuticals LLC | 2 | $28 |
| AstraZeneca | 1 | $28 |
| Bausch Health US, LLC | 1 | $22 |
| UCB, Inc. | 1 | $22 |
| Eisai Inc. | 1 | $18 |
| Banner Life Sciences, LLC | 1 | $15 |
| MDD US Operations, LLC | 1 | $14 |
| Neurocrine Biosciences, Inc. | 1 | $14 |
| Lilly USA, LLC | 1 | $13 |
| Biohaven Pharmaceuticals, Inc. | 1 | $12 |
| Acadia Pharmaceuticals Inc | 1 | $12 |
| Strongbridge US Inc. | 1 | $11 |
| Akcea Therapeutics, Inc. | 1 | $11 |
How this compares
$880,606 in reported general payments places this provider in the 95th percentile of 941 neurology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other neurology in West Reading
- David WeismanAbington$9.3M
- Amit Bar-OrPhiladelphia$7.7M
- Thomas LeistPhiladelphia$5.8M
- Jan DrappatzPittsburgh$4M
- Lauren ElmanPhiladelphia$3.3M
- David IrwinPhiladelphia$2.5M
- Paula ClemensPittsburgh$2.1M
- Anoopum GuptaPittsburgh$2M
- Daniel KremensPhiladelphia$1.9M
- Frances JensenPhiladelphia$1.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.